Vascular parkinsonism (VP) is treated through a combination of dopamine-boosting medication, aggressive management of cardiovascular risk factors, and physical rehabilitation focused on gait. Unlike idiopathic Parkinson’s disease, VP is caused by small strokes or chronic reduced blood flow in the brain, so treatment has two goals: improving movement symptoms and preventing further vascular damage.
How VP Differs From Parkinson’s Disease
Vascular parkinsonism tends to appear at an older age than typical Parkinson’s disease and looks different clinically. The hallmark is a gait disturbance often described as “lower-body parkinsonism,” with shuffling steps, balance problems, and freezing when trying to walk. Rest tremor, the classic shaking hand associated with Parkinson’s, is rare in VP, showing up in only about 12% of confirmed cases. Visual hallucinations are essentially absent, which helps distinguish it from Parkinson’s disease where hallucinations can occur with medication use.
These differences matter for treatment because they explain why VP responds less predictably to the same medications that work well for Parkinson’s disease. The underlying problem isn’t primarily a loss of dopamine-producing brain cells but rather damage to the pathways that carry movement signals, caused by vascular injury.
Levodopa: Partial but Worth Trying
Levodopa, the cornerstone medication for Parkinson’s disease, works for some people with VP but not nearly as reliably. Estimates of how many VP patients respond to levodopa range from about 13% to 50%, depending on the study and how “response” is defined. A reasonable middle estimate is that roughly 30% of VP patients see meaningful improvement.
The people most likely to benefit are those whose brain damage happens to be located in or near the pathways that use dopamine. Brain imaging can help identify these patients. In one study of 17 VP patients treated with levodopa, three had an excellent response, nine had a good response, and two showed moderate improvement during the first year, while three had no response at all.
Because of this unpredictability, clinical guidelines recommend that anyone with suspected VP receive a proper trial of levodopa at an adequate dose (at least 450 mg per day) for at least one year before concluding the medication doesn’t work. Typical doses in studies average around 440 mg per day, though some patients need up to 1,000 mg. Even among those who do respond initially, long-term benefit tends to fade, so expectations should be realistic.
Controlling Vascular Risk Factors
Since VP is fundamentally a vascular condition, preventing further strokes and blood vessel damage is just as important as managing movement symptoms. This means treating the same risk factors that drive heart disease and stroke: high blood pressure, high cholesterol, diabetes, and smoking.
Current cardiovascular guidelines recommend a blood pressure target below 130/80 mmHg for adults with cerebrovascular disease. Reaching this target has also been shown to help prevent cognitive decline and dementia, both of which can accompany VP. Cholesterol management typically involves high-intensity statin therapy to lower LDL levels and slow the progression of atherosclerosis in the brain’s blood vessels.
Antiplatelet medications play a central role in secondary prevention. These drugs reduce the tendency of blood to form clots, lowering the risk of recurrent strokes. Aspirin is the most commonly used, though other options exist. Studies in patients with vascular brain damage show that antiplatelet agents reduce the risk of recurrent cerebral infarctions and generally improve long-term outcomes for stroke survivors. If you have VP, you can expect your doctor to review your full cardiovascular profile and likely start or adjust medications targeting blood pressure, cholesterol, blood sugar, and clot prevention.
Physical Therapy and Gait Training
Physical rehabilitation is a critical part of VP treatment because the gait problems that define the condition respond well to targeted training strategies, sometimes better than they respond to medication.
External cues are one of the most effective tools. White lines on the floor, a metronome beat, or rhythmic music can help people with parkinsonian gait disorders walk with longer steps and a more normal pace. Research has shown that many patients who are cognitively intact can immediately walk with longer, faster steps simply by focusing their attention on step length, even without floor markers. Mental strategies like visualizing long steps, reading reminder cue cards, or verbally reciting phrases like “think big” or “long steps” can also help.
For people with mild to moderate symptoms, therapists generally recommend high-intensity practice sessions three to five times per week for six to eight weeks until the improved movement pattern becomes more automatic. Regular booster sessions over the long term help maintain gains. For those with more severe symptoms or cognitive impairment, the approach shifts to compensatory strategies: repetitive drilling of specific movements, avoiding multitasking during walking, using external cues and reminders, and breaking complex actions into simple segments.
Beyond gait training, other forms of exercise matter. Strengthening the quadriceps muscles through resistance training has been shown to increase walking distance and improve stair navigation. Aerobic conditioning improves oxygen consumption, movement efficiency, and overall walking ability. Exercises targeting spinal and trunk flexibility improve functional reach and balance. A typical program for flexibility involves exercising three to five times per week for six to twelve weeks, depending on how much mobility has been lost.
What About Deep Brain Stimulation?
Deep brain stimulation (DBS), which is an established surgical treatment for Parkinson’s disease, is not a standard option for vascular parkinsonism. DBS works by electrically stimulating specific brain areas involved in dopamine signaling, and its effectiveness depends on the patient having a clear response to levodopa. Since most VP patients respond poorly to levodopa and the underlying brain damage is diffuse vascular injury rather than localized dopamine cell loss, DBS is not typically considered appropriate.
Long-Term Outlook
VP tends to progress in a pattern that differs from Parkinson’s disease. Rather than the slow, steady decline seen in Parkinson’s, VP progression often follows a stepwise course tied to additional vascular events. Each new small stroke or period of reduced blood flow can cause a noticeable worsening. This is exactly why controlling vascular risk factors is so important: preventing the next vascular event is the most effective way to slow the disease.
The levodopa response, when present, often diminishes over time. This makes the non-medication strategies (physical therapy, exercise, and cardiovascular risk management) increasingly important as the disease progresses. People with VP benefit from a long-term, multidisciplinary approach combining neurology, cardiology or primary care for vascular management, and ongoing physical therapy rather than relying on any single treatment.